Advertisement

Individuelle Einschätzung des Risikos der venösen Thrombose

  • I. Scharrer
Conference paper

Zusammenfassung

Das Risiko einer venösen Thrombose unter oralen Ovulationshemmern ist bei Patientinnen signifikant erhöht, die an einem Antithrombin-III-Mangel leiden, eine homozygote F-V-Leiden-Mutante aufweisen, einen Mangel an freiem Protein S haben, Träger von Multigendefekten sind oder bei denen Antiphospholipidantikörper im Blut nachweisbar sind. Bei diesen Patientinnen liegt eine Kontraindikation für die Einnahme von Ovulationshemmern vor.

Neben der Abklärung der Thrombophilie und der Erhebung der Eigen- und Familienanamnese muß eine Beratung bezüglich der Thromboserisikosituationen erfolgen.

Die individuelle Einschätzung des Risikos der venösen Thrombosen umfaßt auch Hinweise auf die praktischen Konsequenzen für die Patientin hinsichtlich der Lebens- und Verhaltensweise, der Vermeidung von Rezidiven, der Art, Dauer und Intensität von Prophylaxe und Therapie sowie eine Vererbungsberatung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM et al. (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 246:1593–1596CrossRefGoogle Scholar
  2. 2.
    Boven HH von, Reitsma PH, Rosendaal FR et al. (1996) Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 75:417–421PubMedGoogle Scholar
  3. 3.
    Bridey F, Wolff M, Laissy JP et al. (1995) Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost 74 (5):1379–1387Google Scholar
  4. 4.
    Conard J, Samama M, Salomon Y (1972) Antithrombin III and the oestrogen content of combined oestro-progestagen contraceptives. Lancet 2:1148–1149PubMedCrossRefGoogle Scholar
  5. 5.
    Dahlbäck B (1996) Are we ready for factor V Leiden screening? Lancet 347:1346–1347PubMedCrossRefGoogle Scholar
  6. 6.
    Fijnheer R, Horbach DA, Donders RC et al. (1996) Faktor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost 76 (4): 514–517PubMedGoogle Scholar
  7. 7.
    Heistinger M, Rumpel E, Iliasch H et al. (1992) Cerebral sinus thrombosis in a patient with hereditary protein S deficiency: case report and review of the literature. Ann Hematol 64:105–109PubMedCrossRefGoogle Scholar
  8. 8.
    Hellgreen M, Svensson PJ, Dahlbäck B (1995) Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynaecol 173:210–213CrossRefGoogle Scholar
  9. 9.
    Hirsch DR, Mikkola KM, Marks PW (1996) Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 131/6:1145–1148PubMedCrossRefGoogle Scholar
  10. 10.
    Jobin F, Vu L, Lessard M (1991) Two cases of inherited triple deficiency in a large kindred with thrombotic diathesis and deficiencies of antithrombin III, heparin cofactor II, protein C and protein S. Thromb Haemost 66:295–299PubMedGoogle Scholar
  11. 11.
    Klinke S, Ehrenforth S, Zwinge B, Scharrer I (1997) Onset of thromboembolic disease in large number of patients with homozygous factor V mutation. Thromb Haemost [Suppl Florence, June 97:308 (Abstract)Google Scholar
  12. 12.
    Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM (1994) Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84:1031–1035PubMedGoogle Scholar
  13. 13.
    Koelman BPC, Rumpt D van, Hamulyak K et al. (1995) Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 74:580–583Google Scholar
  14. 14.
    Koelman JH, Bakker CM, Pladsoen WC et al. (1992) Hereditary protein S deficiency presenting with cerebral sinus thrombosis in an adolescent girl. J Neurol 239:105–106PubMedCrossRefGoogle Scholar
  15. 15.
    Koller H, Stoll G, Sitzer M et al. (1994) Deficiency of both protein C and protein S in a family with ischemic strokes in young adults. Neurology 44:1238–1240PubMedGoogle Scholar
  16. 16.
    Malm J, Laurell M, Dahlbäck B (1988) Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 68:437–443PubMedCrossRefGoogle Scholar
  17. 17.
    Mandel H, Brenner B, Berant M et al. (1996) Coexistence of hereditary homocysteinuria and factor V Leiden — Effect on thrombosis. N Engl J Med 334:763–768PubMedCrossRefGoogle Scholar
  18. 18.
    Mannucci PM, Valsecchi C, Krachmalnicoff A et al. (1989) Familial dysfunction of protein S. Thromb Haemost 62:763–766PubMedGoogle Scholar
  19. 19.
    Meinardi JR, Henkens CMA, Heringa MP, Meer J van der (1997) Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice. Blood Coagul Fibrinolysis 8:152–154PubMedCrossRefGoogle Scholar
  20. 20.
    Norris LA, Bonnar J (1996) The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol 103:261–267PubMedCrossRefGoogle Scholar
  21. 21.
    Osterud B, Robertsen R, Asvang GB, Thijssen F (1994) Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis 5:853–854PubMedCrossRefGoogle Scholar
  22. 22.
    Pabinger I, Schneider B and the GTH Study Group on Natural Inhibitors (1994) Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 71 (5):548–552PubMedGoogle Scholar
  23. 23.
    Pihusch R, Coutre P de, Salat C, Göhring P, Poley S, Hiller E (1996) 19 jährige Patientin mit Thromboembolie unter oraler Kontrazeption. Internist 37:1163–1166PubMedGoogle Scholar
  24. 24.
    Pini M, Manotti C, Pattacini C et al. (1995) High prevalence of activated protein C resistance in young women with venous thromboembolic events occurred during treatment with oral contraceptives. Thromb Haemost 73:1376 (Abstract)Google Scholar
  25. 25.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88/10:3698–3703PubMedGoogle Scholar
  26. 26.
    Quehenberger P, Loner U, Kapiotis S et al. (1997) Effects of third generation oral contraceptives containing newly developed progestagens on fibrinolytic parameters. Fibrinolysis Proteolysis 11 (2):97–101CrossRefGoogle Scholar
  27. 27.
    Rintelen C, Mannhalter C, Ireland H et al. (1996) Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 93:487–490PubMedCrossRefGoogle Scholar
  28. 28.
    Rosendaal FR (1997) End of the line for “third-generation-pill” controversy? Lancet 340:1113–1114Google Scholar
  29. 29.
    Rosing J, Tans G, Nicolaes GAF et al. (1997) Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 97:235–238CrossRefGoogle Scholar
  30. 30.
    Schambeck CM, Schwender S, Haubitz I et al. (1997) Selective screening for the factor V Leiden mutation: Is it advisable prior to the prescription of oral contraceptives? Thromb Haemost (in Druck)Google Scholar
  31. 31.
    Seligsohn U, Zivelin A (1997) Thrombophilia as a Multigenic Disorder. Thromb Haemost 78 (1):297–301PubMedGoogle Scholar
  32. 32.
    Simioni P, Prandoni P, Lensing AWA et al. (1997) The risk of recurrent venous thromboembolism in patients with an Arg606 →Gm mutation in the gene for factor V (Factor V Leiden). N Eng J Med 336/6:399–403CrossRefGoogle Scholar
  33. 33.
    Vandenbroucke JP, Koster T, Briet E et al. (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 334:1453–1457CrossRefGoogle Scholar
  34. 34.
    Villa P, Aznar J, Mira Y, Fernández MA, Vayá A (1996) Third-generation oral contraceptives and low free protein S as a risk for venous thrombosis. Lancet 347:397PubMedCrossRefGoogle Scholar
  35. 35.
    Zöller B, Berntsdotter A, Frutos PG de, Dahlbäck B (1995) Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85:3318–3323Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • I. Scharrer

There are no affiliations available

Personalised recommendations